PainReform Stock (NASDAQ:PRFX), Trade Ideas

PainReform

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACDC

ADXN

BACK

BENF

BNED

BSGM

CGEM

CLDI

CSLR

CTNM

DFLI

DYNT

ERIC

ITCI

JAGX

KAVL

MCBC

MNSO

PACB

PALI

PRFX

PRSO

PRZO

RNAC

RVYL

SKIL

SMXT

SPRC

SXTC

SYTA

TAOP

WISA

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ACOR

ADIL

ASTI

BNRG

BPTS

CISS

DCGO

DECK

DOGZ

DXYZ

EZGO

GRRR

ICCT

IFBD

IMRN

KITT

MGAM

MRIN

MRNO

NEOV

NOVA

NUTX

OPEN

RETO

RVMD

TSLA

VERB

VIAO

VINO

Shares of  Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

GLMD

INAB

MSFT

PSMT

SLNA

Shares of  PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

PainReform Ltd

<p>Nerdwallet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate.  The company reported quarterly sales of $161.900 million which beat the analyst consensus estimate of $156.995 million by 3.12 percent.  This is a 4.54 percent decrease over sales of $169.600 million the same period last year.</p>


Earnings

Earnings Beats

NRDS

Nerdwallet Q1 2024 GAAP EPS $0.01, Inline, Sales $161.900M Beat $156.995M Estimate

<p>VeriSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) reported quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.86 by 3.23 percent. This is a 12.94 percent increase over earnings of $1.70 per share from the same period last year.  The company reported quarterly sales of $384.30 million which beat the analyst consensus estimate of $381.85 million by 0.64 percent.  This is a 5.46 percent increase over sales of $364.40 million the same period last year.</p>


VRSN

VeriSign Q1 Adj $1.92 Beats $1.86 Estimate, Sales $384.30M Beat $381.85M Estimate

Microsoft Intelligent Cloud Revenue Increased 21%, Productivity And Business Processes Revenue Increased 12%, More Personal Computing Revenue Increased 17%

WIIM

INTC

Intel shares are trading lower after the company reported worse-than-expected Q1 sales results and issued EPS guidance below estimates.

<p>Robert Half International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.62 by 1.61 percent.  The company reported quarterly sales of $1.475 billion which missed the analyst consensus estimate of $1.488 billion by 0.84 percent.  This is a 14.04 percent decrease over sales of $1.716 billion the same period last year.</p>


Earnings Misses

Robert Half International Q1 2024 GAAP EPS $0.61 Misses $0.62 Estimate, Sales $1.475B Miss $1.488B Estimate

<p>Princeton Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPRN#NASDAQ">BPRN</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.65 by 4.62 percent. This is a 28.42 percent decrease over earnings of $0.95 per share from the same period last year.</p>


BPRN

Princeton Bancorp Q1 EPS $0.68 Beats $0.65 Estimate

Guidance

GILD

Gilead Sees FY24 Adj. EPS $3.45-$3.85

Buybacks

GOOG

GOOGL

Alphabet Board Authorized Repurchase Of Additional $70B Of Class A And Class C Shares

<p>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.27 by 18.52 percent.  The company reported quarterly sales of $921.000 million which beat the analyst consensus estimate of $909.238 million by 1.29 percent.  This is a 24.21 percent increase over sales of $741.500 million the same period last year.</p>


DXCM

DexCom Q1 2024 Adj EPS $0.32 Beats $0.27 Estimate, Sales $921.000M Beat $909.238M Estimate

Alphabet shares are trading higher following better-than-expected Q1 results.

<p>Ratings for Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $32.25, along with a high estimate of $36.00 and a low estimate of $29.00. This upward trend is apparent, with the current average reflecting a 8.7% increase from the previous average price target of $29.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714075429_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Trustmark among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fitzsimmons</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Brad Milsaps</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Trustmark. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Trustmark compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Trustmark's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Trustmark's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRMK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Trustmark analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Trustmark</h2>
<p>Trustmark Corp is a s a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee and Texas. Its principal products and services include, Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services and others. The company is managed along three operating segments; General Banking, Wealth Management and Insurance. The General Banking segment which generates the majority of the revenue provides all traditional banking products and services, including loans, deposits and also consists of internal operations.</p>
<h3>Trustmark: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Trustmark's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-3.17%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Trustmark's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>22.49%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.24%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Trustmark's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.38</strong>, Trustmark adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

TRMK

In-Depth Examination Of 4 Analyst Recommendations For Trustmark

<p>Business Outlook</p>
<p>Intel's guidance for the second quarter of 2024 includes both GAAP and non-GAAP estimates. Reconciliations between GAAP and non-GAAP financial measures are included below.</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"><strong>Q2 2024</strong></td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1"><strong>GAAP</strong></td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1"><strong>Non-GAAP</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$12.5-13.5 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">40.2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">43.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">61%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">13%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings (Loss) Per Share Attributable to Intel—Diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(0.05)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.10</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>Actual results may differ materially from Intel's business outlook as a result of, among other things, the factors described under "Forward-Looking Statements" below. The gross margin and EPS outlook are based on the mid-point of the revenue range.</p>


Intel Sees Q2 EPS $0.10 Vs $0.24 Est.; Revenue $12.5B-$13.5B Vs $12.68B Est.

<p>T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) reported quarterly earnings of $2.00 per share which beat the analyst consensus estimate of $1.89 by 5.82 percent.  The company reported quarterly sales of $19.594 billion which missed the analyst consensus estimate of $19.811 billion by 1.09 percent.  This is a 0.19 percent decrease over sales of $19.632 billion the same period last year.</p>


TMUS

T-Mobile US Q1 2024 GAAP EPS $2.00 Beats $1.89 Estimate, Sales $19.594B Miss $19.811B Estimate

Gilead Sciences Sees FY24 Sales $27.1B-$27.5B Vs $27.982B

<p>Deep-pocketed investors have adopted a bullish approach towards MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSCI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for MSCI. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 43% bearish. Among these notable options, 12 are puts, totaling $462,147, and 4 are calls, amounting to $128,720.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $420.0 and $480.0 for MSCI, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for MSCI's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MSCI's whale trades within a strike price range from $420.0 to $480.0 in the last 30 days. </p>
<h3>MSCI Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714075410_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$17.2</td>
<td>$16.2</td>
<td>$16.3</td>
<td>$440.00</td>
<td>$114.8K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">240</td>
</tr>
<tr>
<td>MSCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$16.6</td>
<td>$16.0</td>
<td>$16.6</td>
<td>$440.00</td>
<td>$43.1K</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">144</td>
</tr>
<tr>
<td>MSCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$12.8</td>
<td>$12.3</td>
<td>$12.5</td>
<td>$420.00</td>
<td>$40.0K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">103</td>
</tr>
<tr>
<td>MSCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$24.7</td>
<td>$24.2</td>
<td>$24.5</td>
<td>$480.00</td>
<td>$39.2K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">17</td>
</tr>
<tr>
<td>MSCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$25.0</td>
<td>$24.6</td>
<td>$25.0</td>
<td>$480.00</td>
<td>$35.0K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">60</td>
</tr>
</tbody>
</table>
</p>
<h3>About MSCI</h3>
<p>MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1.4 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.</p>
<p>Following our analysis of the options activities associated with MSCI, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of MSCI</h3>
<ul>
<li>Trading volume stands at 1,233,041, with MSCI's price up by 0.41%, positioned at $466.57.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>Professional Analyst Ratings for MSCI</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $571.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from UBS keeps a Buy rating on MSCI with a target price of $575. </li>
<li>Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $638.</li>
<li>An analyst from Deutsche Bank upgraded its action to Buy with a price target of $569. </li>
<li>An analyst from B of A Securities has decided to maintain their Underperform rating on MSCI, which currently sits at a price target of $425. </li>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on MSCI with a target price of $648. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for MSCI, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

MSCI

MSCI's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in APP usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for AppLovin. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 75% leaning bullish and 16% bearish. Among these notable options, 4 are puts, totaling $126,110, and 8 are calls, amounting to $558,222.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $85.0 for AppLovin, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AppLovin's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AppLovin's whale trades within a strike price range from $25.0 to $85.0 in the last 30 days. </p>
<h3>AppLovin Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714075404_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$72.50</td>
<td>$270.0K</td>
<td style="text-align: right;">891</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$22.9</td>
<td>$21.1</td>
<td>$22.2</td>
<td>$60.00</td>
<td>$75.4K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">34</td>
</tr>
<tr>
<td>APP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$14.0</td>
<td>$13.9</td>
<td>$14.0</td>
<td>$77.50</td>
<td>$44.8K</td>
<td style="text-align: right;">26</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.5</td>
<td>$13.2</td>
<td>$13.3</td>
<td>$75.00</td>
<td>$41.2K</td>
<td style="text-align: right;">116</td>
<td style="text-align: right;">62</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.3</td>
<td>$13.2</td>
<td>$13.3</td>
<td>$75.00</td>
<td>$41.2K</td>
<td style="text-align: right;">116</td>
<td style="text-align: right;">31</td>
</tr>
</tbody>
</table>
</p>
<h3>About AppLovin</h3>
<p>AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.</p>
<h3>AppLovin's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,966,686, the price of APP is down by -0.55%, reaching $69.32.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>Expert Opinions on AppLovin</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $81.8.</p>
<ul>
<li>Reflecting concerns, an analyst from Daiwa Capital lowers its rating to Neutral with a new price target of $80.</li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on AppLovin with a target price of $70. </li>
<li>Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for AppLovin, targeting a price of $87. </li>
<li>An analyst from BTIG persists with their Buy rating on AppLovin, maintaining a target price of $87. </li>
<li>An analyst from Oppenheimer persists with their Outperform rating on AppLovin, maintaining a target price of $85. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AppLovin with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


AppLovin Unusual Options Activity

<p>High-rolling investors have positioned themselves bullish on Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SCHW often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Charles Schwab. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $28,515, and 7 calls, totaling $409,201.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $72.0 to $95.0 for Charles Schwab during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Charles Schwab's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Charles Schwab's significant trades, within a strike price range of $72.0 to $95.0, over the past month.</p>
<h3>Charles Schwab Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714075399_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.15</td>
<td>$80.00</td>
<td>$157.3K</td>
<td>1.3K</td>
<td style="text-align: right;">506</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.86</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$80.00</td>
<td>$57.0K</td>
<td>2.7K</td>
<td style="text-align: right;">420</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$3.65</td>
<td>$3.25</td>
<td>$3.6</td>
<td>$95.00</td>
<td>$56.9K</td>
<td>197</td>
<td style="text-align: right;">784</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$4.65</td>
<td>$4.5</td>
<td>$4.58</td>
<td>$82.50</td>
<td>$45.8K</td>
<td>1.6K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$1.84</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$75.00</td>
<td>$34.0K</td>
<td>3.5K</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>
</p>
<h3>About Charles Schwab</h3>
<p>Charles Schwab operates in brokerage, wealth management, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of December 2023. Nearly all of its revenue is from the United States.</p>
<p>Following our analysis of the options activities associated with Charles Schwab, we pivot to a closer look at the company's own performance.</p>
<h3>Charles Schwab's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,038,232, the SCHW's price is down by -0.77%, now at $74.61. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What The Experts Say On Charles Schwab</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $80.6.</p>
<ul>
<li>An analyst from Piper Sandler persists with their Overweight rating on Charles Schwab, maintaining a target price of $78. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Charles Schwab with a target price of $89. </li>
<li>An analyst from B of A Securities persists with their Underperform rating on Charles Schwab, maintaining a target price of $70. </li>
<li>An analyst from Barclays has decided to maintain their Equal-Weight rating on Charles Schwab, which currently sits at a price target of $74. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Charles Schwab, targeting a price of $92. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Charles Schwab with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


SCHW

Decoding Charles Schwab's Options Activity: What's the Big Picture?

<p>Alphabet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>) reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.51 by 25.17 percent.  The company reported quarterly sales of $80.539 billion which beat the analystAlphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.51 by 25.17 percent.  The company reported quarterly sales of $80.539 billion which beat the analyst consensus estimate of $78.594 billion by 2.47 percent.  This is a 15.41 percent increase over sales of $69.787 billion the same period last year. </p>


Alphabet Q1 2024 GAAP EPS $1.89 Beats $1.51 Estimate, Sales $80.539B Beat $78.594B Estimate

<p>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(1.49) by 11.41 percent.  The company reported quarterly sales of $6.10 billion which missed the analyst consensus estimate of $6.34 billion by 3.79 percent.  This is a 3.97 percent decrease over sales of $6.35 billion the same period last year.</p>


Gilead Sciences Q1 2024 Adj EPS $(1.32) Beats $(1.49) Estimate, Sales $6.10B Miss $6.34B Estimate

<p>Ratings for Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.8, with a high estimate of $32.00 and a low estimate of $15.00. This current average has increased by 15.44% from the previous average price target of $19.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714075354_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Gap is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jenny Liu</td>
<td>KGI Securities</td>
<td>Announces</td>
<td>Outperform</td>
<td>$25.20</td>
<td>-</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gap. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gap compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Gap's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gap's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GPS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Gap analyst ratings.</strong></a></p>
<h2>About Gap</h2>
<p>Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates approximately 2,600 stores in North America, Europe, and Asia and franchises more than 900 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.</p>
<h3>Breaking Down Gap's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Gap showcased positive performance, achieving a revenue growth rate of <strong>1.3%</strong> as of 31 January, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Gap's net margin excels beyond industry benchmarks, reaching <strong>4.3%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Gap's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>7.32%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Gap's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.67%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.1</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Gap's Future

Painreform Ltd. (PRFX) has released an update. PainReform Ltd., an Israel-based company, has announced that its shareholders approved all proposals...

PainReform Shareholders Approve Key Proposals

Painreform Ltd. (PRFX) has released an update. PainReform Ltd. has announced positive results from their studies, showing that their non-opiate tre...

PainReform's PRF-110 Sets New Pain Relief Benchmark

AEYE, GSIT and VVPR among mid-day movers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!</p>



<p>Moving stocks this morning are shareholder meetings, clinical updates, an annual report and delisting plans.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Marin Software</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/"><strong>MRIN</strong></a>) stock is rocketing more than 67% after <a href="https://finance.yahoo.com/news/marin-software-enhances-microsoft-advertising-202000808.html">upgrading its integration</a> with <strong>Microsoft </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) Advertising.</li>



<li><strong>iCoreConnect</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/icct-stock-quote/"><strong>ICCT</strong></a>) shares are soaring over 39% alongside heavy pre-market trading.</li>



<li><strong>Nano Labs</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/na-stock-quote/"><strong>NA</strong></a>) stock is surging more than 35% after <a href="https://www.nasdaq.com/press-release/nano-labs-files-annual-report-on-form-20-f-for-fiscal-year-2023-2024-04-08">filing its 2023 annual report</a>.</li>



<li><strong>Jaguar Health</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/jagx-stock-quote/"><strong>JAGX</strong></a>) shares are increasing over 34% after <a href="https://finance.yahoo.com/news/jaguar-health-reports-approval-proposals-201500942.html">revealing results from its shareholder meeting</a>.</li>



<li><strong>IN8bio </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/inab-stock-quote/"><strong>INAB</strong></a>) stock is gaining more than 22% <a href="https://www.nasdaq.com/press-release/in8bio-announces-new-preclinical-data-for-gamma-delta-nscar-t-cell-therapy-platform">alongside preclinical data</a>.</li>



<li><strong>Meiwu Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/wnw-stock-quote/"><strong>WNW</strong></a>) shares are heading over 16% higher with strong early morning trading.</li>



<li><strong>Quantum </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/qmco-stock-quote/"><strong>QMCO</strong></a>) stock is climbing more than 14% despite a lack of news this morning.</li>



<li><strong>iSpecimen </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ispc-stock-quote/"><strong>ISPC</strong></a>) shares are rising close to 14% without any clear news this morning.</li>



<li><strong>African Agriculture</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/"><strong>AAGR</strong></a>) stock is jumping over 11% today.</li>



<li><strong>Galmed Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/glmd-stock-quote/"><strong>GLMD</strong></a>) shares are up more than 10% on Wednesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Ascent Solar Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/asti-stock-quote/"><strong>ASTI</strong></a>) stock is plummeting more than 49% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318227158&amp;type=PDF&amp;symbol=ASTI&amp;cdn=6c900f5f936acd98ef3c512d6e5bb28d&amp;companyName=Ascent+Solar+Technologies+Inc&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-04-09">launching a public offering</a>.</li>



<li><strong>FutureFuel </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/ff-stock-quote/"><strong>FF</strong></a>) shares are diving over 28% after <a href="https://www.nasdaq.com/press-release/futurefuel-to-release-first-quarter-2024-financial-results-on-may-9-2024-2024-04-08">announcing a date</a> for its upcoming earnings report.</li>



<li><strong>Velo3D </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/"><strong>VLD</strong></a>) stock is tumbling more than 27% after announcing a <a href="https://finance.yahoo.com/news/velo3d-announces-proposed-public-offering-210000442.html">proposed public offering</a>.</li>



<li><strong>Biophytis </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/"><strong>BPTS</strong></a>) shares are taking an over 20% beating <a href="https://investorplace.com/2024/04/why-is-biophytis-bpts-stock-up-43-today/">following a rally yesterday</a>.</li>



<li><strong>PainReform </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/"><strong>PRFX</strong></a>) stock is falling more than 19% as it <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318225142&amp;type=PDF&amp;symbol=PRFX&amp;cdn=db9014d6a36df8779dda82dcce26f5b4&amp;companyName=PainReform+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-09">continues negative movement from yesterday</a>.</li>



<li><strong>VIA Optronics</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/"><strong>VIAO</strong></a>) shares are dropping over 19% <a href="https://www.businesswire.com/news/home/20240409050064/en/VIA-optronics-AG-Announces-Intention-to-Voluntarily-Delist-its-ADSs-from-the-New-York-Stock-Exchange">on delisting plans</a>.</li>



<li><strong>Destiny Tech100</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/"><strong>DXYZ</strong></a>) stock is sliding more than 18% <a href="https://investorplace.com/2024/04/dxyz-stock-what-to-know-about-the-new-destiny-tech100-fund-taking-over-wall-street/">alongside recent volatility</a>.</li>



<li><strong>Selina Hospitality</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/"><strong>SLNA</strong></a>) shares are decreasing over 18% after a massive rally yesterday.</li>



<li><strong>Mobile Global Esports</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/"><strong>MGAM</strong></a>) stock is dipping more than 16% after rallying on Tuesday.</li>



<li><strong>Telesis Bio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/"><strong>TBIO</strong></a>) shares close out our pre-market stock movers down over 15% after announcing <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318226530&amp;type=PDF&amp;symbol=TBIO&amp;cdn=5f941c4bf6eb8c3db6101ae988f298d1&amp;companyName=Telesis+Bio+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-04-09">shareholder meeting details</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-10th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

BSGM, WAVE and TCBP among pre-market losers

Aptevo Therapeutics, TRACON Pharmaceuticals, Biosig Technologies among healthcare movers

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ – Research Report), PainRefor...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), PainReform (PRFX) and IN8bio (INAB)

PainReform prices its $4M offering at $0.80 apiece; shares fall

Painreform Ltd. (PRFX) has released an update. PainReform Ltd. has announced a $4 million public offering of 5 million shares and warrants, with pr...

PainReform Ltd. Launches $4 Million Public Offering

Painreform Ltd. (PRFX) has released an update. PainReform Ltd. has announced an amendment to their existing warrants, effectively reducing the exer...

PainReform Ltd. Adjusts Warrant Terms

AAGR

ACRV

AEHL

AEYE

ANGH

APVO

AUUD

BCAN

CADL

CLRO

GSIT

ISPC

LASE

LIFW

MDIA

MSGM

PDYN

QMCO

SILO

SOUN

TBIO

TCBP

TCON

VVPR

WAVE

ZOOZ

Press Releases

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Provides Business Update for the Third Quarter of 2023

Financing

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

General

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Provides Year-End Business Update

Health Care

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Announces Pricing of $4 Million Public Offering

PainReform Announces Closing of $4 Million Public Offering